Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9386159 | 0.86 | CA12 (0.39) | FFAR4ALDH1A1 | |
| SCHEMBL5065145 | 0.84 | ALDH1A1 (0.38) | FFAR4ALDH1A1 | |
| Bromide SCHEMBL4939222 | 0.82 | ALDH1A1 (0.41) | FFAR4ALDH1A1 | |
| SCHEMBL11997826 | 0.78 | SLC22A2 (0.38) | FFAR4ALDH1A1 | |
| SCHEMBL8863421 | 0.78 | BCL2 (0.42) | FFAR4ALDH1A1 | |
| SCHEMBL11997831 | 0.77 | SLC22A2 (0.36) | FFAR4ALDH1A1 | |
| SCHEMBL11997829 | 0.74 | FFAR4 (0.35) | FFAR4 | |
| SCHEMBL11995120 | 0.64 | ACHE (0.36) | ALDH1A1 | |
| SCHEMBL11997836 | 0.62 | ADORA2A (0.40) | ALDH1A1 | |
| SCHEMBL11997820 | 0.59 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754232-B2 | Methods of making bis-tridentate carbene complexes of ruthenium and osmium | UNIVERSAL DISPLAY CORPORATION (US) | 2014-06-17 | — | — | US | disclosed |
| US-20140021453-A1 | METHODS OF MAKING BIS-TRIDENTATE CARBENE COMPLEXES OF RUTHENIUM AND OSMIUM | UNIVERSAL DISPLAY CORPORATION (US) | 2014-01-23 | — | — | US | disclosed |
| US-8563737-B2 | Methods of making bis-tridentate carbene complexes of ruthenium and osmium | UNIVERSAL DISPLAY CORPORATION (US) | 2013-10-22 | — | — | US | disclosed |
| US-20120215000-A1 | METHODS OF MAKING BIS-TRIDENTATE CARBENE COMPLEXES OF RUTHENIUM AND OSMIUM | UNIVERSAL DISPLAY CORPORATION | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120215000-A1 | METHODS OF MAKING BIS-TRIDENTATE CARBENE COMPLEXES OF RUTHENIUM AND OSMIUM | OCIAD2, OCIAD1, OSTC | FFAR4 3811/4885ALDH1A1 4073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.